Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today reported its third quarter 2014 financial results and updated its 2014 financial guidance based on the commencement of its global strategic collaboration with AbbVie Inc. to develop and commercialize duvelisib (IPI-145), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in oncology. Earlier today, Infinity announced that five abstracts, including three oral presentations, describing clinical and preclinical translational data for duvelisib will be presented at the American Society of Hematology (ASH) 2014 Annual Meeting, which is being held December 6-9 in San Francisco, California.
Help employers find you! Check out all the jobs and post your resume.
